Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The companies have worked together since 2023. Eli Lilly is doubling down on AI drug development with its latest deal. Eli Lilly ( LLY ) is expanding its partnership with Insilico Medicine, a Hong Kong-based firm that is developing drugs with AI tools, the companies announced late Sunday. The deal gives the Zepbound and Mounjaro maker an exclusive license to sell any of Insilico's drugs that make it to the market, with the companies also collaborating on drug development. "Insilico's AI-enabled discovery capabilities represent a powerful complement to Lilly's deep expertise in clinical development across multiple therapeutic areas," Eli Lilly's group vice president of Molecule Discovery Andrew Adams said. Why This Matters to Investors Eli Lilly and other drugmakers have partnered with AI companies like Insilico and OpenAI to use AI tools with the goal of finding new treatments for diseases. The latest agreement suggests Eli Lilly is bullish about the potential of the techno
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR Newswire
- Franklin Rising Dividends Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Eli Lilly's CEO Says This Could Be a Game Changer for Its Business [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its price target lowered by Guggenheim from $1,168.00 to $1,163.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website